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The design of inhibitors subject to the constraint that they only bind within
the shape occupied by the substrate has been identified as a useful strategy
to avoid drug resistance (termed the substrate envelope hypothesis). This
eﬀectively limits the interactions a ligand makes with the receptor to those
also made by the substrate or substrates, which reduces the opportunity for
mutations that disrupt inhibitor binding without also disrupting substrate
binding. We have developed a systematic inverse design approach that
searches for optimal binders that satisfy the substrate-geometry constraint
using a hierarchical re-scoring procedure; it includes an initial fast grid-
based evaluation followed by use of more sophisticated energy functions
to improve energetic accuracy. This approach has been applied to design
high-aﬃnity human immunodeficiency virus (HIV-1) protease inhibitors
with subnanomolar binding aﬃnities and relatively flat binding profiles
when tested against a panel of resistant variants. Here we have applied
the inverse method to design robust inhibitors for the shallow, solvent
exposed, substrate-binding groove of hepatitis C virus (HCV) NS3/NS4A
protease, using a serine trap warhead to covalently anchor the inhibitor
scaﬀold to the protease. This work introduces novel methodology for the
covalent ligand attachment incorporated into the design procedure using a
thermodynamic-cycle framework to treat the conformational change and
covalent bond accompanying binding. The design resulted in a collection
of inhibitors that make substrate-like interactions. The binding energy
calculations revealed that they remained minimally aﬀected by known
prevalent resistance mutations (Arg 155 and Ala 156) losing only a maximum
of 1 kcal ·mol−1 for Arg 155 and less than 15 kcal ·mol−1 for Ala 156. In
comparison, the inhibitors Boceprevir, ITMN-191, and TMC-435 lost nearly
15 kcal ·mol−1 for Arg 155 and 35 kcal ·mol−1 for Ala 156. Furthermore, our
analysis validates the substrate envelope hypothesis by demonstrating that
v
systematic design approaches can lead to high-aﬃnity inhibitors computed
to be less susceptible to resistance than ordinary candidates, even when
considering this shallow, solvent-exposed binding site.
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Preface
Structure-based drug design is a process in which the three-dimensional
structure of the target protein is understood and analyzed to design drugs to
combat human diseases [1]. Computational methods play an important part
in obtaining the information from the structures to eﬃciently design the
ligands [1]. The structures considered for computational analysis are mainly
obtained from X-ray crystallography or NMR [2, 1]. Homology modeling
is used in cases where the experimental structures are not available[2, 1].
The accuracy of the structural information is paramount for optimal ligand
design. While the major application of computational methods in the past
was limited to improving existing ligands, recent computational approaches
focus mainly on developing de-novo compounds and generating a database
of ligands that can be screened virtually to find lead compounds [1]. Before
being made available as a drug to the public, the identified lead compound
has to go through several stages of animal studies and clinical trials, where
critical factors such as toxicity, bioavailability and drug resistance play
significant roles [1].
Computational drug design is performed either by docking a library
of compounds from databases, or through de novo drug design methods
[2, 3, 1]. De novo drug design methods focus on identifying the functional
groups on the ligands that have the potential to bind and interact well with
the target [1]. Scoring functions determine the success of docking ligands
into the binding site of the target molecules. It includes a combination of
enthalpic and entropic factors contributing to the ligand binding such as
x
hydrogen bonding, van der Waals interactions, electrostatic interactions,
solvation contributions, hydrophobic eﬀect and internal energy (bond, angle
and torsion terms) [1, 4].The free energy change is computed for the ligands
and a negative free energy change indicates favorable association.
Since the automated design of small molecules was limited by the molec-
ular search space and the requirement for a fast and eﬃcient scoring mecha-
nism, a de novo inverse drug design method [5] was implemented in the Tidor
laboratory. This method used the target structure and knowledge about the
binding site to solve the inverse shape and inverse electrostatics problem to
determine the optimal theoretical ligand with the best binding properties
[6, 7, 8]. This method aims to solve the inverse shape problem considering
a negative image of the binding site. The more challenging inverse electro-
static problem requires determining the optimal charge distribution that a
ligand should have to minimize the electrostatic component of its binding
energy. Previous studies [6, 7, 8] from the Tidor laboratory had solved
the inverse electrostatics problem using a continuum electrostatics model
where solute and solvent are represented by low and high homogeneous
dielectric medium respectively. The partial atomic charges of the atoms are
represented by point charges within the low dielectric region and the ions
are treated using Debye-Huckel treatment. The linear poisson-Boltzmann
equation gives the electrostatic binding free energy, and the ligand charges
that optimizes the binding free energy can be obtained using a matrix
equation [6, 7, 8] derived from its solution in the bound and unbound state.
Furthermore, the scaﬀold and functional group search was employed to
get compounds with optimal charge distributions. The scoring function
included the van der Waals energy, electrostatic interaction and solvation
terms. Since a constant shape was assumed for the ligand in the combinato-
rial search, the hydrophobic term is a constant and hence not calculated.
The obtained compounds were later re-scored with their exact molecular
xi
shape. The method incorporates flexibility in ligand poses by considering
conformational ensembles along with ligand protonation, tautomerism and
stereoisomerism, while keeping the receptor fixed. Considering structural
waters explicitly could improve accuracy by providing stabilization through
specific hydrogen bonding and van der Waals interaction [2, 3], but implicit
treatment is preferred to optimize the computational time required. Even
though the solvent environment was treated implicitly in the calculation,
water molecules from the experimental structures that are within 3A˚ of the
biomolecules are considered explicitly as a part of the biomolecule during
computational analysis.
Covalent docking is one of the recent advances in the computational
docking methods [1]. Covalent docking could prove useful in gaining insights
into enzymatic processes and in designing covalent ligands. Although a
few softwares like Autodock 4.0 provide the functionality to dock ligands
covalently, to the best of our knowledge de novo ligands designed with
covalent attachment to the receptor has never been reported previously.
Considering a change in shape from unbound to bound when searching
the ligand space in a design is challenging for two reasons. One reason
is that it will be computationally expensive to consider conformational
changes in the ligand poses as well as in the receptor, and the second
is that the computation of free energy changes between the bound and
unbound structures for building the scoring function is challenging. The
inverse method uses linear poisson-boltzmann equation to handle the inverse
electrostatic problem and requires bound and unbound state calculations.
It assumes same shape for both the states and follows a thermodynamic
process not designed to handle conformational change, making it unsuitable
for design with conformational change.
This thesis presents a methodological advancement to the inverse de-
sign protocol that implements a novel thermodynamic cycle framework to
xii
compute the desolvation taking into account the shape change while also
enabling the design method to be computationally eﬃcient. This includes
critical modifications to the matrix equation and to the decomposition of
the scoring function. This inverse design methodology with conformational
change can be applied to cases where covalent binding induces a shape
change in both the receptor and the ligand. In this thesis, the inverse
design methodology with conformational change is implemented and applied
to design inhibitors with covalent anchoring to the shallow active site of
Hepatitis C virus (HCV) NS3/4A protease.
Chapter 1 introduces the significance of Hepatitis C, the target HCV
NS3/4A protease and challenges due to resistance mutations. It explains
the substrate envelope hypothesis used to handle the challenge, and the
inverse drug design methodology that implements the substrate envelope
hypothesis to design robust inhibitors.
Chapter 2 describes the inverse design methodology with conformational
change, and introduces the newly developed thermodynamic process to
handle the conformational change and its implementation in the scoring
function at required places of the methodology. This chapter also explains
the details of computational methods applied and some specifically required
when considering the HCV NS3/4A protease system.
Chapter 3 describes the validation of the implementation, the results of
the design and its analysis. The work also tries to find the eﬃciency of the de-
signed inhibitors in comparison to few commercial and candidate inhibitors,
and its robustness considering prevalent resistance mutations making use
of the experimental results available for the considered commercial and
candidate inhibitors.
and Chapter 4 concludes the work.
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Chapter 1
Hepatitis C Virus and
Inhibitor design
1.1 Significance
Hepatitis C virus (HCV) is a pathogen of global priority as it causes a
significant health problem aﬀecting more than 170 million people (3% of
the world population) chronically, with an increase of 3-4 million new cases
every year. Acute infection generally does not show any symptoms, and
during initial stages the immune system is capable of bringing the infection
under control. In some cases, the immune system can even eliminate the
virus completely [9, 10]. But in 70% of the cases the virus evades the
immune system through various strategies leading to a chronic disease state
[11, 12, 13]. Transmitted by blood-borne or sexual routes, HCV replication in
hepatocytes persists for decades leading to chronic hepatitis, liver cirrhosis,
and hepatocellular carcinoma [12, 13] as long term consequence. The
prolonged infection can be possible only from a complex interplay between
the virus and the host which includes: the virus evading the innate and
adaptive immune system, regulating its replication, producing new virions,
and maintaining a balance between the virus induced hepatocyte death and
liver regeneration [13]. This threat could become a serious problem in the
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coming years if left unattended.
HCV is classified as a member of the Flaviviridae family, and it is the
sole member of genus Hepacivirus [14]. Flaviviridae also includes genera
Flavivirus and Pestivirus. Members of Flavivirus include yellow fever virus
and dengue virus, and that of Pestivirus include classical swine fever virus
(CSFV) and bovine viral diarrhoea virus (BVDV). Even though HCV is
the only member of hepacivirus genus, it is diverse in terms of genetic
profile [15]. Currently it has 6 genotypes, and several subtypes (genotype
designated with numbers and subtypes with letter modifiers on the parental
genotype number; such as 1a, 1b, 2a etc.) [16, 17]. Genotypes diﬀer in
sequence similarity by 30 - 35% and the subtypes diﬀer from each other by
20 - 25% [17, 9, 18, 19].
Further, the HCV RNA-dependent RNA polymerase lacks the proof
reading activity that leads to error prone replication of the viral genome.
The mutation rate of HCV replication has been estimated to be about 10−4
misincorporations per nucleotide [16] and it is estimated that 1012 virions
are produced per day in an infected individual [20, 10]. The relatively small
genome size together with the error prone and large replication number make
the HCV exist as a pool of closely related sequence containing population
termed as ”quasispecies” in an infected person, making it diﬃcult for the
host immune system to clear the infection.
1.2 Life cycle
HCV is an enveloped virus with a diameter of about 50 nm [21], and
the genome is an uncapped single stranded RNA of 9.6 kilo base size with
positive polarity. During infection, HCV complexes with the host lipoprotein
particles in the serum. These particles binds to the receptor of the host cell
and enter the cell through clatherin mediated endocytosis. The vesicle has
a low pH and endosome acidification activates the fusion of viral membrane
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with the endosomal vesicle. This results in the release of the positive strand
RNA that serves as a messenger RNA inviting the host ribosome to translate
it.
The viral genome encodes a polypeptide chain of approximately 3000
amino acids in length, with conserved 5’ and 3’-untranslated regions nec-
essary for replication and translation. The 5’ – non-coding region consists
of an internal ribosome entry site (IRES) that binds to the 40S ribosomal
subunit directly inducing a bound mRNA conformation. This complex
then associates with eukaryotic initiation factor 3 (eIF 3) and Met-tRNA-
eIF2-GTP to form 48S intermediate to transit kinetically slowly to form
translationally active 80S complex [22], thereby leading to the translation
of the message by the host ribosome.
Following translation, the host and viral proteases cleave the polyprotein
into at least 10 mature HCV proteins, all associated with the membrane.
They include structural proteins — the viral core protein C and glycoproteins
(E1, E2); the ion channel protein (p7), and non-structural proteins (NS2,
NS3, NS4A, NS4B, NS5A, NS5B). The structural proteins become functional
after cleavage by signal peptidases. The p7/NS2 junction is also cleaved
by the signal peptidases. The NS2/3 junction is cleaved by the viral NS2
cysteine protease. The rest of the polypeptide chain (NS3/4A, NS4A/4B,
NS4B/5A, NS5A/5B) is cleaved by NS3 protease [23, 24, 25, 26, 27]. The
proteins then move to appropriate compartments within the cell to carry
out their respective functions. The proteins NS4B, NS5A and NS5B then
form the replication complex and the positive strand acts as the template
to synthesize the negative strand. Then the negative strand is used as
the template to produce a large number of positive strand RNAs [28, 19].
Some of these RNAs passes through the translation process, some generate
more negative strands for replication, and the rest serve as substrates for
the virion assembly. For virion assembly, the genomic RNA is brought
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Figure 1.1: Lifecycle of HCV: The virus binds to receptor; enters the cell
through endocytosis; releases the RNA; translates and processes itself; as-
sembles the replication machinery, synthesizes the negative strand; replicates
the positive strand into excess copies and finally packages and releases the
virons.
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from the membraneous web created by non-structural proteins for viral
RNA replication, to the nucleocapsid core protein. Following which the
nucleocapsids form and bud into the endoplasmic reticulum by association
of the core with the viral glycoprotein spikes. The new virions associates



































Figure 1.2: Topology and function of the viral proteins resulting from the
cleavage of HCV genome. The cleavage sites and respective responsible
proteins are marked by arrows.
1.3 Target selection
The preferred way to target infection is either by boosting the host defense
system or by targeting the viral proteins that are essential for the replication.
Both these approach have been shown to be eﬀective. The standard of
care(SOC) for patients with chronic hepatitis C till recently was daily oral
dose of ribavirin with a weekly injection of pegylated interferon-α (IFN-α)
[29]. This treatment is only 40% eﬀective against genotypes 1a and 1b, but
70% eﬀective against genotype other than 1a and 1b. Also, the side eﬀects
of this treatment includes depression, fatigue and ”flu-like” symptoms caused
5
by IFN-α, and hemolytic anemia caused by ribavirin, necessitating the need
to find a new drug with fewer side eﬀects [29]. The other targets are the
four viral non-structural proteins that help in the viral RNA replication-
NS2 cysteine protease, NS3/4A serine protease, NS3 helicase and NS5B
polymerase, of which the NS3/4A serine protease and NS5B polymerase are
the most attractive targets for design of oral drugs due to their immense
potential to control the HCV replication. [29].
NS2 cysteine protease plays a major role by processing the NS2/3
substrate and releasing the NS3 protein that takes responsibility for the
following steps to ensure replication [9, 13]. The NS3 protein is a multi-
functional protein with both the N-terminal protease and C-terminal helicase
domain [22, 13]. The NS3/4A protease belongs to the serine protease family
with a typical chymotrypsin like fold, placing the conserved catalytic residues
serine 139, histidine 57, and aspartate 81 on the interface between two beta-
barrel domains [22, 13]. It is a hetero-dimer complex with the NS3 protease
catalytic subunit and NS4A cofactor[22, 13]. For complete folding and full
activity, NS3 protease requires intercalation with the beta strand of NS4A
[22, 13]. NS4A is a protein of 54 amino acids in length that anchors to the
membrane with its N terminal hydrophobic patch [22, 13]. As a cofactor
binding to NS3 protease, at least the central 14 hydrophobic residues are
found to be essential [13]. Also, it is found that Zn2+ coordination with 3
cysteine residues distal from the active site is necessary for the structural
stability of NS3 protease [9, 22, 29].
The NS3/4A serine protease not only helps in cleaving the polypro-
tein but also is found to abrogate the immune response mediated by the
transcription factor interferon regulatory factor 3 (IRF-3) [9, 30]. IRF-3
stimulates the production of type-I interferon and also other antiviral genes
during infection. The protease inhibits IRF-3 stimulation by blocking RIG-I












Figure 1.3: 1CU1- NS3 protein with both the protease and helicase domains
(adapted from [28]).
[30, 13]. This function of the protease provides the virus significant advan-
tage to evade the immune response, as the 2 major pathways that control
interferon (IFN) production in the hepatocytes would be stopped. Also,
by controlling IFN production, the protease controls the IFN amplification
loop and interferon Stimulating Genes (ISG) production that has an eﬀect
over antigen processing and presentation, as the Major Histocompatibity
Complex (MHC) components are ISG products. In addition, the proteases’
control over the nuclear factor-κ B (NF-κ B) [13] can cause serious immune
defects, as NF-κ B is responsible for expression of various chemokines and cy-
tokine genes. Further, IRF-3 is said to have tumor suppressor functions [30].
This could be a possible reason for hepatocellular carcinoma development
during persistent HCV infection [30].
The NS3 helicase has functions that include RNA-stimulated nucleoside
triphosphatases (NTPase) activity; RNA binding and unwinding of RNA
regions, and the NS3 protease and NS5B are hypothesized to modulate
the helicase activity. NS4B is an integral membrane protein that anchors
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the replication complex, and it is found to modulate NS5B. NS5A is a
phosporylated zinc-metalloprotein that helps in replication and is found
to modulate NS5B but the mechanism remains unclear [22]. NS5B is a
tail-anchored protein with an RNA polymerase domain. It is thus a very
important protein that could synthesis HCV RNA with both positive and
negative polarity [22, 31, 32, 33].
In summary, a study of HCV biology suggests potential therapeutic
targets — NS2, NS3 protease, NS3 helicase and NS5B polymerase [9].
The NS3 protease and helicase, and NS5B polymerase are found to have
significant homology to other known enzymes, and hence are attractive
targets. Targeting the HCV NS3 protease has been shown to reduce infection
significantly [29]. The conservation of the enzymes’ active site across
genotypes and the established mechanism of action, and its important role
in immune escape by abrogating the immune response mediated by IRF-3,
makes it is a desirable therapeutic target. Further, the confidence given
by the success of HIV protease based drugs and the challenges they posed
have left us the knowledge to develop better eﬃcient inhibitors targeting
the protease [29].
1.4 Complexities associated with HCV drug
development
There was no proper culture system for studying HCV until 1999 though
the sequence of HCV was reported in 1989. HCV aﬀects only humans
and chimpanzees [29]. It took nearly 20 years to understand the HCV
biology. HCV research gathered momentum in 1999 when it was reported
by Lohmann et al. [34] that subgenomic replicons consisting of only the
non-structural proteins with antibiotic resistance gene along with the 5’
and 3’ non-coding sequences could replicate in Huh-7 cell line from human
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liver. This discovery opened doors to study and gather information about
HCV [22]. Successful design of HIV protease inhibitors have raised hopes
for developing drugs for other proteases. Unlike HIV protease that had a
deep well protected substrate binding pocket, the HCV NS3/4A protease
had a shallow solvent exposed substrate binding pocket [35]. So serine
trap warheads are used to covalently anchor the inhibitor scaﬀolds and to
increase their aﬃnity to the HCV NS3/4A protease [29].
1.5 NS3/4A serine protease inhibitors
Although attempts to find chemical inhibitors for HCV NS3/4A by screening
varies chemical compound libraries has failed [36], eﬃcient peptidomimetic
inhibitors were derived from NS5A/NS5B substrate of the enzyme using
structure-based drug design methods [29]. The discovery of inhibition of
HCV NS3/4A protease by its cleavage products has played a significant
role in designing peptide-mimetics [37]. The structure-based drug design
method that was used to find the peptide-mimetics calculates the surface
area and volume of the active site pocket and manipulates the substrate/
product residues such that the inhibitor can occupy and interact with the
active site to the maximum [38].
Two classes of inhibitors were found to inhibit the HCV protease - macro-
cyclic and electrophilic warhead (serine warhead) containing compounds.
Of the electrophilic warheads the α -ketoamides was reported to perform
better than the aldehydes, keto acids and di-ketones [29].
The first protease inhibitor that showed high eﬃciency in terms of
inhibition was BILN-2061, a non-covalent, macro-cyclic inhibitor. Cell line
and animal studies showed that the treatment resulted in a significant
decline in HCV RNA levels, and this was the first inhibitor to demonstrate
that targeting the HCV NS3/4A protease eﬀectively stops RNA replication
of the virus. Not only did it help us understand the potential of targeting
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the HCV NS3/4A protease but also the seriousness of the selection of
resistant mutants to the inhibitor. However, this inhibitor was halted from
further study as it caused myocardial toxicity in animals [39]. A few other
macro-cyclic inhibitors are in the clinical trials [40, 41].
Currently there are 2 other FDA approved linear ketoamide protease in-
hibitors that show significant control over HCV RNA replication: Telaprevir
(VX-950) and Boceprevir (SCH503034) [42]. Both are covalent reversible
serine warhead containing inhibitors. With the product backbone, the in-
hibitors were obtained by optimizing the P4 - P’1 groups such that it shows
very good binding activity. Telaprevir administration is generally associated
with anemia, neutropenia, leukopenia [43], rashes, and gastro-intestinal ad-
verse eﬀects. While boceprevir has not been reported to produce rashes, its
use is associated with anemia [44], and its potency compared to Telaprevir
is less. Importantly, both drugs have to be administered in combination
with IFN-alpha and ribavirin to reduce the chances of selection of resistant
mutants.
1.6 Drug resistance
As discussed in section 1.1, the HCV is highly variable and rapidly mutating.
The higher the variability, the chances of getting a good working vaccine
is lower. The importance of the virus existing as quasispecies can be
appreciated when selective pressure is applied to the population. In the
presence of selective pressure in a quasispecies, the virus instead of evolving
resistance to avoid the pressure can simply pick a mutant that can avoid the
selective pressure from the existing pool of diverse mutants [13]. The picked
mutant will quickly become dominant and also accumulate further mutations
to enhance the replication of this sequence [13]. Hence the small molecule
drugs targeted against virus containing a particular sequence could lead
to speedy development of drug resistance. This is the reason for following
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a combination therapy. To avoid drug resistance, the existing inhibitors
are given in combination with pegylated interferon-α (IFN-α) and ribavirin.
Combination therapy does have its drawback as it is mostly not tolerated well
by the patients due to the treatment duration and dosage [45, 46]. Thus, the
need for a single molecule drug that can handle development of resistance by
inhibiting wild-type as well as any existing and emerging functional mutants.
Mutations and their eﬀects on commercial and candidate inhibitors have
already been studied experimentally [47, 46]. Table 1.1 shows existing
and candidate inhibitors’ decrease in inhibition potency due to prevalent
mutations, hinting that problems due to resistance mutations are closer and
that the problem for a cure for HCV is still far from getting solved.
Table 1.1: Drug resistance in commercial and candidate inhibitors
Mutation EC50(nM)
Inhibitor wt R155K R155T A156T A156V
Boceprevir 148 743 (4.7) 5463 (51) 7227 (65) 9673 (75)
ITMN-191 0.5 135 (447) 48 (261) 4.8 (41) 12 (63)
TMC-435 11 260 (30) 314 (24) 377 (44) 2149 (177)
Teleprevir 150 1470 (10) 22663 (74) 20326 (105) 15470 (112)
* values in paranthesis represents fold change.
1.7 Substrate envelope hypothesis
One of the eﬃcient ways to handle the resistance mutation problem is
designing inhibitors that do not extend out of the substrate volume. The
Schiﬀer laboratory identified the substrate envelope hypothesis as a strat-
egy to generate robust inhibitors – correlating the extended volume of the
protruding bound inhibitor fragments to loss in inhibitor binding aﬃnity
[48]. Generally inhibitors are designed in such a way that they make the
maximum possible interactions to ensure strong binding. These inhibitors
are found to select for resistant mutants. But the substrates, unlike the
inhibitors, make only few essential interactions. Hence, designing inhibitors
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that fit within the shape and volume of the substrate is expected to behave
like the substrate avoiding unnecessary interactions thereby reducing the
emergence of resistance mutations. The so-called ”substrate envelope hy-
pothesis” posits that robust inhibitors can be designed by requiring that
their bound conformation does not extend outside the shape and volume of
the bound substrates in the enzyme active site — mutations that disrupt
inhibitor binding would also disrupt substrate binding, and so would be
non-functional.
1.8 Inverse Design Methodology for Small
Molecule Drug Discovery
Structure-based computational design methods combine the best-available
experimentally determined protein structures, accurate yet eﬃcient models
of chemical interactions, synthetically accessible virtual libraries of appro-
priate inhibitor candidates, and eﬃcient search methods to identify library
members most chemically compatible with tight-binding to the active site
while also satisfying additional criteria, such as the substrate envelope
hypothesis. To test this hypothesis making use of computation, an inverse
design based drug-design method was developed in the Tidor lab to develop
robust binding inhibitors. The inverse design method takes the protein
structure and the substrate envelope placed in the active site as inputs.
Unlike forward approaches in which molecules are virtually screened and
scored to find inhibitors, this is an approach where inhibitors are designed
from fragments.
The inverse design methodology [5, 49] follows three main steps. Gen-
erating a fixed shape for inhibitors to be designed within the constraint,
grid-based energy calculation to handle the combinatorial explosion, and

































































































































































































































































































































































































algorithm to search for globally optimal and progressively sub optimal
energy structures.
The receptor and substrate are selected and with these as input, a
substrate envelope is created by obtaining a negative image of the receptor
binding pocket where the substrate binds. This remains as a hard constraint
on the size and shape of the designed ligands as well as an approximation to
the molecular shape in the solvation calculation. Then grid-based energy is
computed for van der Waals packing, electrostatic desolvation, and screened
electrostatic interaction on cubic lattices within the shape as these are
the three primary components of the scoring function employed in the
combinatorial search procedure.
Next, the scaﬀold and the building blocks to be used for the design
are selected and prepared by optimizing their structure and obtaining
partial atomic charges. First, the scaﬀold is docked within the substrate
envelope and conformations that make good interactions and that do not
clash with the receptor are selected. Then the scaﬀold conformers are
checked with the smallest possible side group or a small set of building
blocks comprising molecules ranging from the smallest to the largest in
size depending on the mode of attachment of the side groups, to eliminate
scaﬀold conformers that can not be extended at every attachment position.
This reduces computational time by excluding useless scaﬀold conformers
before calculation. For each scaﬀold conformation, self and pair-wise energies
for the functional group rotamers are computed using grid-based energies.
Then the dead end elimination (DEE) algorithm [50, 51, 52] is employed
to search for the global minimum binding energy configuration and the
compounds are ranked using the A* algorithm [53]. DEE is a discrete
search algorithm that finds rotamers that cannot be part of the global
minimum energy conformation (GMEC) thereby eﬀectively reducing the
computational explosion of the rotamer combinatorial problem. Thus it
14
Red – Protease; Blue – NS4A cofactor; 
Pink – Helicase mimic; Licorice - substrate 
Red – Protease; Blue – NS4A cofactor; 
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Side groups and Design
Figure 1.5: Overview of inverse drug design. Substrate envelope was
generated using the bound substrate (a) to represent both the bound as
well as the unbound state. Grid-based energy functions were computed
on cubic lattices within the shapes (b). Van der Waals, desolvation and
interaction energies were computed using the generated substrate envelope.
The scaﬀold was prepared (c) and the conformational ensemble was searched
by translating and using torsional sampling within the envelope (d). The side
groups that can attach to the scaﬀold were picked and discrete conformations
were generated (e). The design (f) was carried out placing the scaﬀold in
the envelope and calculating the single and pairwise energies. Guaranteed
search algorithms were applied to find the global optimal and suboptimal
structures that were ranked according to their energies.
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allows determining the global minimum energy conformations for large
rotamers list [50, 51, 52]. A* algorithm [53] is a path traversal algorithm
that finds the low cost path and is known for its accuracy and performance.
Here it is used to rank the compounds found using DEE. Then the best
compounds are re-ranked using higher energy functions.
This approach was previously tested with HIV-1 protease and was shown
to give good robust binders of subnanomolar inhibition [5]. The design
produced 36 compounds with aﬃnities between 14pM and 4 nM with some
compounds having only a maximum aﬃnity loss of 14 - 16 fold when tested
against a panel of resistant variants [5]. Crystal structures of a subset of
the protease inhibitor complexes revealed binding modes that respected the
envelope and were similar to the design [5]. Substrate envelope hypothesis
assumes that the substrate similarity could be captured with the envelope
and the interaction it makes with the receptor [5]. This study established the







Inverse design with conformational change follows similar methodology
as without conformational change, as was applied to the HIV-1 protease
[5]. Both implement the substrate envelope restraint in identifying robust
inhibitors. The system studied in this work — HCV NS3/NS4A — includes
a requisite conformational change. Here we have devised a thermodynamic
pathway that correctly describes the conformational change in terms that
can readily be computed. The pathway includes steps for desolvating
the unbound-state molecules, changing conformation in uniform dielectric,
binding in uniform dielectric, and resolvating the complex formed. The
first and the last steps produce solvation contributions, and the second
step produces coulombic self energy and docking energy contributions.
The whole inverse design procedure utilizes an initial restraint — fixed
shapes in the target binding site, one representing the bound state and one
representing the unbound state. In this chapter, I introduce the inverse
drug design methodology considered to design inhibitors for HCV NS3/4A
protease and describe the thermodynamic process that properly handles the
17
conformational changes. This approach finds its use when a specific mode
of binding needs to be exploited to identify strong binding inhibitors or to
include induced binding in the design.
Red – Protease; Blue – NS4A cofactor; 











Substrate envelope - bound and unbound
Scaffold and Ensemble considering non-rigid binding
Side groups and non-rigid Design
Figure 2.1: Overview of inverse drug design with conformational change.
Substrate envelopes were generated capturing the dynamics of the substrate
(a) to represent the bound and unbound state. Grid-based energy functions
were computed on cubic lattices within the shapes (b). Van der Waals, bound
solvation and interaction energies were computed using the bound-state
envelope and the unbound solvation was computed using the unbound-state
envelope. The scaﬀold was designed considering the feasibility of synthesis
to include the inhibiting functional group and diversity inducing chemical
entity (c) and the conformational ensemble was searched using torsional
sampling within the bound envelope (d). The side groups that can attach
to the scaﬀold were picked and discrete conformations were generated (e).
The design (f) was carried out placing the scaﬀold in the envelope and
calculating the single and pairwise energies. Guaranteed search algorithms
were applied to find the global optimal and suboptimal structures that were
ranked according to their energies.
2.1 Definition - rigid and non-rigid binding
The conformational change referred to here represents the shape change
in ligand and receptor when it transits from unbound to bound state. In
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any real case, receptor and ligand can adopt diﬀerent conformations for
the bound and unbound state. Often for computational calculations, the
conformation of the ligand and receptor in their bound as well as unbound
state are assumed to be the same, which is termed rigid binding. But if
the ligand and receptor’s bound and unbound conformation is assumed to
change, the binding is termed nonrigid. Figure 2.2 explains the diﬀerence






Figure 2.2: Rigid and non-rigid binding. The figure shows two bound state
conformations with one representing a simple association of unbound ligand
and receptor with their shape not considered to change (rigid), and the
other showing the conformational change in both the receptor and ligand
(non-rigid).
2.2 HCV NS3/4A protease – structure selec-
tion, substrate modeling and protease
preparation
Information on all available protein structures of HCV protease were col-
lected from public databases and the details of the structures were tabulated,
including ligands bound in complex, quality of structure, and presence of
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allosteric factors, such as the activating peptide. We sought to select a
protease structure that mimicked the functional state of HCV NS3/4A
protease. There were over 30 structures of NS3 protease available in the
public databases. Mutant structures were eliminated, and structures were
checked for the presence of necessary cofactors (NS4A, Zn+2), good reso-
lution (≤ 2.5A˚), buried surface area, and the volume of the binding site.
From the list of experimental structures (Table 2.1) that passed the criteria
of having cofactors, bound ligand and no mutation, 1DY9 and 1CU1 had a
binding site surface area of 164.8A˚2 and 170A˚2, and a volume of 225.7A˚3
and 211.7A˚3 respectively. The calculations were performed using CAST-p
web server [54] that uses the weighted Delaunay triangulation and the alpha
complex [55, 56, 57] for shape measurements. The 1CU1 [58] structure was
the only structure available at that time that contained the helicase domain
in addition to the protease, providing us with an opportunity to study the
significance of the helicase. Moreover it is the only available structure that
contains the cleavage product bound and shows it inhibiting the protease.
With the goal of designing inhibitors that bind within the substrate enve-
lope, finding a substrate bound crystal structure would have been ideal;
but no crystal structure with bound substrate was available. It is reported
by Ingallinella et al. [37] that the P-side derived products resembles the
ground-state binding of respective substrates. Hence the product bound
structure (1CU1 [58]) was selected with a plan to model the rest of the
substrate from the product. Since our electrostatic potential calculations
showed that a small number of important residues from the helicase were
the most significant, we removed the helicase domain and retained only the
identified most significant residues. In this context, the remaining important
residues (P1’ – P4’) constituting the substrate were modeled. The substrate
was modeled both in its non-covalently and covalently bound state.
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Table 2.1: HCV NS3/4A protease structures with resolution ≤ 2.5A˚
PDB id NS4A Resolution Zn+2 Ligand Mutation
2O8M yes 2 yes no yes
1DY9 yes 2.1 yes yes no
1JXP yes 2.2 yes no no
1W3C yes 2.3 no yes yes-NS4A
2OC0 yes 2.3 yes yes yes-NS4A
3EYD yes 2.3 yes yes yes-NS4A
1A1Q no 2.4 yes no no
1DXP yes 2.4 yes no no
1DY8 yes 2.4 no yes no
2A4R yes 2.4 yes yes yes
2QV1 yes 2.4 yes no no
2A4Q yes 2.45 yes yes no
1A1R yes 2.5 yes no yes-NS4A
1CU1 yes 2.5 yes yes no
2A4G yes 2.5 yes yes no
2GVF yes 2.5 yes yes no
2OBQ yes 2.5 yes no yes-NS4A
2OIN yes 2.5 yes no yes
2.2.1 Importance of the HCV NS3 helicase
Calculations were done to identify portions of the HCV NS3 helicase that
aﬀect substrate and inhibitor binding to the protease. Electrostatic poten-
tial calculations were done using a locally modified version of the DelPhi
software package [59, 60]. The interaction energy of the non-covalently
bound substrate with the receptor and the desolvation calculation for the
substrate were aﬀected in the structure considered without the helicase
domain (diﬀerence in energy between the structure with helicase and with-
out helicase – protease-substrate interaction energy: −1.54 kcal · mol−1;
substrate desolvation: 3.95 kcal ·mol−1). To gain a deeper insight, residue-
by-residue calculations were done with the substrate. This showed that the
glutamate in P4 position of the substrate made a strong interaction with
the helicase, showing that it loses −1.04 kcal ·mol−1 of protease-substrate
interaction energy and misses 2.52 kcal ·mol−1 of substrate desolvation in
the structure without helicase. Visualizing the structure revealed that the
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P4 glutamate’s carbonyl oxygen interacted with the helicase’s glutamine
526. Performing calculation with 526 instead of the helicase domain recov-
ered −0.549 kcal ·mol−1 of the −1.536 kcal ·mol−1 lost protease-substrate
interaction energy, and 1.36 kcal · mol−1 of the 3.954 kcal · mol−1 ligand
desolvation penalty.
The NS3 protein has a N-terminal protease domain and a C-terminal
helicase domain as explained chapter 1 (section 1.3). The 1CU1 structure
showed the protease active site occupied by the helicase C terminus, i.e.,
the structure showed a stable molecular conformation with the cleavage
product (P6-P1) bound as an extended anti-parallel β-strand. So performing
calculations with the nearby residues to 526 (527-531) along with the
residues in the helicase C-terminus close to the substrate (623-625) recovered
−1.405 kcal ·mol−1 of the lost protease-sustrate interaction and 3.751 kcal ·
mol−1 of the ligand desolvation penalty.
Because the presence of the helicase could be mimicked using these sets
of residues, the helicase was removed and these two sets of residues were
retained. Replacing the helicase requires abrupt termination of the residues.
So patches mimicking peptide-like extensions were provided by adding acetyl
and N-methylamide blocking groups for the N-terminus and C-terminus,
respectively, while preparing the two sets. The C-terminal patch to the
residue set 623 to 625 that defines the end of the receptor can not be added
since this residue set extends as the substrate (626-631). Furthermore, since
the conformation of this residue set when a drug binds is not known, the
623-625 residue set was excluded with a loss of only −0.42 kcal · mol−1
protease-substrate interaction value and missing only 1.13 kcal · mol−1 of
ligand desolvation penalty. The recently published crystal structure (4A92
[61]) of an NS3/4A protease-helicase structure complexed with inhibitor
ITMN-191 analog has reported distorted residues (623-631) in the diﬀraction
data indicating that we cannot make any clear conclusions about those
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Figure 2.3: Cartoon represents the helicase domain; red surface represents
the protease; blue represents the NS4A cofactor; ice blue represents the
helicase mimic patch 626-631, and pink represents the helicase mimic patch
526-531.
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Figure 2.4: red surface represents the protease; blue represents the NS4A
cofactor and pink represents the helicase mimic 526-531.
residues when an inhibitor/substrate is bound.
2.2.2 Substrate modeling and protease preparation
The 1CU1 [58] structure with only the important residues of the helicase
(residues 526 - 531) was prepared for modeling and design studies. The
water molecules that were more than 3 A˚ away from the protein structure
were removed. The protein preparation required standard approaches that
include assigning appropriate orientation and titration states to ambiguous
side chains, and developing parameters for unusual or non-standard chemical
entities. The flip states were checked for the asparagine, glutamine and
histidine residues and the end rotational bond was rotated 180◦ if it made
better hydrogen bondings with the rest of the residues. The histidines were
given proper protonation and all these were done checking these residues
manually (visualized with locally modified VMD [62] plugin). Asparagine 49,
glutamine 28, the helicase residue glutamine 526, and the histidine 57 were
flipped. The catalytic histidine 57 was given a delta protonation so that it
24

















interaction energy with helicase (wH)
interaction energy no helicase (nH)
Ligand desolvation wH
Ligand desolvation nH
Figure 2.5: Residue 628 (Glu) of the substrate makes good interaction with
protease in the presense of the helicase and gets less desolvation penalty if


























Figure 2.6: Residue 526 and its contiguous residues showed that the helicase
domain could be replaced. Though adding residues 626-631 improves the
mimicking slightly, its conformation when the substrate/inhibitor is bound
is unknown.
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hydrogen bonds with aspartate 81 and the epsilon nitrogen hydrogen bonds
with the serine 139 hydroxyl group. The termini were made peptide-like by
adding the acetyl and N-methylamide blocking groups to the N-terminus and
C-terminus, respectively. Because the substrate had to be modeled based
on the product, the substrate was built in a stepwise fashion extending the
bound product, keeping the whole substrate flexible every time but giving
an increasing gradient harmonic force constraint ranging from 5 kcal ·mol−1
to 60 kcal · mol−1 on the product starting from the C-terminus to the N-
terminus. The gradient constraint was applied to ensure that the crystal
structure was not altered unless it is essential. Iterative minimization was
employed placing the constraints every 100 steps of minimization as the
residues were added. The hydrogen atom positions were built using the
HBUILD [63] functionality in the CHARMM computer program [64], using
distance dependent dielectric constant of 4r.
The bound substrate that results from the preparation represents the
associated state described before (Figure 2.2). The serine protease makes
covalent interactions with the substrate, and since we designed covalent
inhibitors here, the substrate was modeled in its covalently bound form
to the protease. A patch was added to link the serine hydroxyl oxygen
and the substrate’s threonine 631 carbonyl carbon. It works by deleting
the serine hydroxyl hydrogen, creating a bond between the catalytic serine
hydroxyl oxygen and the substrate threonine carbonyl carbon, and giving
the threonine carbonyl oxygen a negative charge. To support this substrate
conformation, the catalytic histidine was doubly protonated while modeling
to account for the proton abstraction by the histidine 57 from the serine
139.
The substrate, both in its non-covalently bound state (Figure 2.7e) and
transition state (Figure 2.7f), was equilibrated keeping its N-terminal patch
harmonically constrained (15 kcal ·mol−1) and the catalytic serine side chain
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Figure 15: Figure showing the modelling of the substrate in a stepwise fashion; a: product with serine 139 as in
the crystal structure; b: P1’ (Ser 632) built; c: P2’ (Thr 633) built; d: P3’(Trp 634) built; e: P4’(Val 635) built; f:
Transition state model of the substrate (Ser 139 bonded to carbonyl carbon of Thr 631)
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Figure 2.7: Stepwise modeling of the substrate. a: product with prot ase’s
catalytic Ser 139 as in the crystal structure; b: P1’ (Ser 632) built; c:
P2’ (Thr 633) built; d: P3’ (Trp 634) built; e: P4’ (Val 635) built; f:
Transition state model of the substrate (protease’s catalytic Ser 139 bonded
to carbonyl carbon of Thr 631); All peptide-like patch endings were applied
while modeling the substrate.
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flexible for 4 ns starting at 400 K, and gradually reducing the temperature
by 100 K steps every 1 ns to check for the existence of any other stable local
energy minimum conformation. In both the cases, the modeled substrate,
remained stable in the binding pocket ensuring that there was no substrate
conformation that significantly diﬀered from the starting structure. The
energy of each saved snap shot from the respective 100 K simulations were
obtained. The best energy substrate structures (non-covalent and transition
state) were picked as input for the respective substrate envelope creation.
2.3 Fixed shape constraint
The inverse ligand design procedure works considering a fixed target shape
such that the atom centers of the generated compounds must stay within its
volume. The fixed shape serves as a constraint on ligand size and also serves
as an approximation to the ligand shape throughout the combinatorial
search over the molecular space. This constant shape consideration facili-
tates continuum electrostatic calculations serving as a constant boundary.
Further, it enables us to do fast grid-based calculations of solvation energies.
Substrate envelope hypothesis was implemented in the design by considering
the fixed shape to be the shape of the substrate and by constraining the size
and shape of the designed ligands to the volume occupied by the substrate.
The substrate coordinates are given as seed to generate the shape by adding
spheres into the binding pocket and accepting spheres that do not clash
with the receptor. In the rigid binding, the bound shape of the substrate
was considered as the fixed shape constraint with the ligand and receptor
assumed to have same shape both in their bound and unbound states. In
case of the nonrigid-binding considered here for the HCV NS3/4A protease,
the threonine carbonyl carbon changes from sp2 configuration to sp3 configu-
ration in the bound state. Hence two envelopes were constructed – with the
bound state envelope constructed from the covalently bound substrate, and
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the non-covalently bound substrate assumed to represent the unbound state
used for the unbound substrate envelope construction. This is a reasonable
assumption to make considering the grid-based solvation calculations we
intend to perform.
2.3.1 Dynamic substrate envelope
Two envelopes were created to represent the bound and unbound state
using the covalently and non-covalently bound substrate respectively. The
ideal shapes for consideration would be the substrate’s shape in its diﬀerent
conformations at the site of interest where the binding occurs. But no
substrate bound experimental structures were available for HCV NS3/4A
protease. So to capture the eﬀective dynamics, the substrate envelope
was generated from substrate snap shots saved at every 200 fs from a
molecular dynamics simulation of the stable low energy structure from
100 K simulation for 6 ns. Both the covalently and non-covalently bound
substrate structure was equilibrated keeping the serine side chain rigid. The
substrate snapshots (P3-P1’) from the simulation were extracted and the
substrate envelope was created by first creating a box of spheres of van
der Waals radius = 1.5 A˚ in the protease active site. The spheres were
added such that they do not clash with the receptor. After the negative
image of the binding site was created, spheres that overlaid with 85% of the
30,000 snapshots were retained and the rest of the spheres were removed.
The spheres were considered clashing/overlaying with the atoms if they
were separated by less than the minimum van der Waals clashing distance
calculated with the assumed radius of the sphere and the van der Waals
radius of the atom. The necessary requirement when creating the bound
state substrate envelope was adding spheres to cover the receptor serine
hydroxyl oxygen to account for the covalent bond. Spheres that had an
unfavorable van der Waals interaction with the protein were rejected. The
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position of the spheres was then minimized using the van der Waals potential
in CHARMM with the receptor fixed. The optimal distance between two
spheres was kept to be 0.45 A˚ and this procedure used the substrate as seed
positions for the spheres, while allowing them to expand further to fill the
site.
Figure 2.8: Bound and Unbound envelope.
2.4 Grid-based potentials
2.4.1 Thermodynamic process for calculation of change
in total electrostatic energy upon intermolecu-
lar binding
The rigid binding follows a two step thermodynamic process to calculate the
change in total electrostatic energy as reported by Gilson and Honig [59],
in which the total electrostatic energy change on binding is given as the
summation of the free energy change in the receptor and ligand solvation
when ligand binds with the receptor and the solvent screened interaction
energy between receptor and ligand. It is written as,
￿Gbindr−l = ￿Gdesolvr +￿Gdesolvl +￿Ginterr−l (2.1)
where,
￿Gdesolvr is the change in the receptor solvation free energy on ligand
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binding.
￿Gdesolvl is the change in the ligand solvation free energy upon binding
with the receptor.
￿Ginterr−l is the solvent screened interaction free energy between the
receptor and the ligand. That is, it is the interaction energy between the
receptor and the ligand in the presence of the solvent.
The thermodynamic process constructed here is shown in figure 2.9. In
the initial step, the receptor and the ligand that are infinitely separated are
partially desolvated by removing the solvent in the region to be occupied
by the binding partner. The work done is given as ￿Gdesolvr +￿Gdesolvl
that represents the change in the charge-solvent interaction upon binding.
The second step involves adding the charges to the binding partner and
computing the interaction between the binding molecules in the presence of
the solvent. This is the solvent screened interaction between the binding
partners given by ￿Ginterr−l .
Thermodynamic process involving conformational change
The implemented thermodynamic-cycle framework serves as an important
methodological advancement to the inverse design methodology by consid-
ering the conformational change involved in the ligand and the receptor
when opting for the non-rigid binding mode. To avoid calculating the
conformational free energy in heterogenous dielectric, we devised a process
in which the molecules are desolvated to homogenous dielectric medium
where the conformational change can be accounted for with the change
in the molecule’s coulombic energy upon conformational change. Hence
the thermodynamic process to calculate the total electrostatic free energy
change is re-written as a four step process that is given as the summation
of solvent screened interaction between ligand and receptor, change in self
coulombic energy of the ligand and receptor due to conformational change in
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uniform low dielectric, and diﬀerence between bound and unbound solvation
free energy of ligand and receptor.
￿Gbindr−l = (￿Gsolvr−b −￿Gsolvr−ub +￿Gcoulombr )+
(￿Gsolvl−b −￿Gsolvl−ub +￿Gcoulombl ) +￿Ginterr−l (2.2)
Here in this expanded equation,
￿Gdesolvl , the change in the ligand solvation free energy upon binding
with the receptor is broken down as ￿Gsolvl−b −￿Gsolvl−ub +￿Gcoulombl
where,
￿Gsolvl−b and ￿Gsolvl−ub are the ligand bound and unbound solvation free
energy, respectively.
￿Gcoulombl is the change in coulombic self energy due to ligand confor-
mational change.
The receptor term can be explained in a similar fashion.
￿Ginterr−l is still the solvent screened interaction energy between the
receptor and ligand.
The developed and implemented thermodynamic cycle process is repre-
sented in the figure 2.10. The first step involves desolvating the unbound
ligand and receptor. The work done is given by −(￿Gsolvr−ub +￿Gsolvl−ub).
The second step gives the change in coulombic self energy upon conforma-
tional change for receptor and ligand (￿Gcoulombr +￿Gcoulombl ). In the third
step the respective bound states are solvated and the associated work is
(￿Gsolvr−b +￿Gsolvl−b ). Note that the binding partner does not have its charges
until the fourth step; previously it is treated as a nonpolar low dielectric re-
gion. The final (fourth) step involves adding charges to the binding partner
and computing the solvent screened interaction between the receptor and


























Figure 2.9: Thermodynamic process for rigid binding.
2.4.2 Electrostatic binding potential calculation con-
sidering conformational change
To account for conformational change, the newly devised thermodynamic
process was implemented while calculating the electrostatic potentials. With
fixed shapes assumed for the bound and unbound state, calculations of
electrostatic grid-based potentials are done by solving the linearized Poisson–
Boltzmann equation and is given as,
￿Gelec = ￿qbTSb￿qb − ￿qubTSub ￿qub + ￿qbT ￿C +Rdes (2.3)
where ￿qb is a charge vector of the bound ligand, ￿qub is a charge vector
of the unbound ligand, Sb is the ligand bound solvation matrix, Sub is
the ligand unbound solvation matrix, ￿C is the screened interaction vector,
and Rdes is the receptor desolvation penalty (a scalar). If the rigid binding











































Figure 2.10: Thermodynamics process for nonrigid binding.
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written as (￿qT (Sb − Sub)￿q). The advantage of considering the solvation terms
separately as (￿qb
TSb￿qb − ￿qubTSub ￿qub) instead of obtaining the desolvation
term directly as (￿qT (Sb − Sub)￿q), is that we could account for the shape
change in the receptor or ligand or both. The interaction vector ￿C is derived
considering only the bound state and charging the receptor atoms to their
parameterized values. The screened electrostatic potential projected by the
receptor charges at each ligand grid point becomes the elements of ￿C. The
receptor desolvation penalty, Rdes, is computed by taking the diﬀerence
between the bound and unbound state receptor solvation energy, where the
receptor is charged and the ligand is kept uncharged. Because both the
bound and unbound target ligand shapes are fixed, this number is a constant
throughout the combinatorial search. Keeping both the bound and unbound
target shape constant allows for the pre-computation of Sbound, Sunbound, ￿C,
and Rdes and is the basis for the fast grid-based electrostatic and solvation
approximation.
2.4.3 Calculation of grid-based potentials
Once the target shape for the bound and unbound states are selected, the
goal of the combinatorial search procedure is to design molecules into the
selected bound shape that interact favorably with the receptor. The inverse
design employs grid-based energy functions and pre-computes potentials
on a regular cubic lattice inside the target shape. Grid potentials are
then interpolated onto the molecules projected onto the grids to compute
binding energies. The scoring function employed in the design procedure
considers three primary components, a van der Waals packing term, a
screened electrostatic interaction term, and desolvation penalties for both
the designed ligand and the receptor.
Grid-based energies for van der Waals scoring [65, 66, 5] were computed
on a regular cubic lattice placed within the target shape with a grid spacing
35
of 0.2 A˚. The parameters used for van der Waals energies were derived
from the general CHARMm22 parameter set [67]. The grid-based van der
Waals energies were computed by placing an atom of specified type at
each grid point within the target shape and calculating its van der Waals
interaction energy with the receptor. This was done for all atom types and
a table was generated. With the grid energy computed, the van der Waals
interaction energy of any given molecule was approximated by summing the
contribution from each atom, derived from trilinear interpolation from the
surrounding eight points on the appropriate atom-type grid.
Grid-based electrostatic solvation and interaction potentials [5] were also
computed on regular cubic lattices within the target sites, with a spacing
of 0.75 A˚ . The S matrices, ￿C vector, and Rdes were computed solving the
linearized Poisson–Boltzmann equation (LPBE) using a locally modified
version of DelPhi. A molecular dielectric constant of 4, a solvent dielectric
constant of 80, a molecular surface probe radius of 1.4 A˚, an ionic-strength
of 145 mM, and an Stern layer of 2.0 A˚ was considered. A 129× 129× 129
finite-diﬀerence grid was employed to compute the elements of S and ￿C,
and a 257× 257× 257 grid was used to compute Rdes. A focusing scheme
was used such that the system was solved first occupying 23% followed by
92% of the grid, transferring boundary potentials from the lower to higher
resolution. An additional over-focusing involving the system occupying
184% of the grid was employed when computing elements of the S matrices
and ￿C vector. This was done to improve the accuracy. Radii for the receptor
proteins was derived from the PARSE parameter set [68], and a radius of
1.5 A˚ was used as the sphere radius.
The symmetric S matrices were generated by charging each grid point to
a value of 1.0e while all other grid points and receptor atoms had a charge of
0.0e, and solving the linearized Poisson-Boltzmann equation with a specific
boundary. The resulting potentials at all of the basis points become one
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column of the S matrix. The ￿C vector was derived from the bound state,
in which the receptor atoms were charged to their parameter values and
the grid points had no charge. Rdes was computed by taking the diﬀerence
between the bound and unbound-state solvation energy keeping the receptor
charged and the grid uncharged.
The electrostatic binding energy for any given molecule inside the tar-
get shape was computed by spreading the partial atomic charges of the
molecule onto the surrounding eight grid points with a trilinear projection.
If several partial atomic charges were projected to the same grid point, their
contribution was added. These grid charges were then used in Equation 2.3
to obtain the electrostatic binding free energy.
With the bound state envelope and the receptor as inputs, the grid-based
potentials were computed for van der Waals packing, electrostatic solvation
and screened electrostatic interactions. The unbound state envelope was
used as the input and the electrostatic solvation energies were computed on a
cubic lattice within the shape. The van der Waals interaction is between the
receptor and the ligand of interest. The presence of the covalent bond that
we have considered between the ligands and the receptor (Figure 2.11) could
assume van der Waals clash between the atoms placed on the grid points
and the receptor, and lead to inaccurate energies on the grids placed on the
extra spheres. Hence the receptor serine side chain atoms were removed
during the van der Waals energy computation. This approach ensures that
we do not miss any good scaﬀold positions by wrongly computing a clash
between the receptor and the scaﬀold atoms. Similarly the conformational
energy (￿Gconf ) that can not be included in the inverse design due to
fixed shape assumption is excluded from the electrostatic calculations. The
compromise in accuracy for both the electrostatic and van der Waals terms
in the low resolution calculations was corrected in the re-evaluation done
using higher resolution energy functions. In addition to van der Waals,
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and electrostatic solvation and interaction terms, a bump check against
the target shape is included to ensure that any molecule outside the target
shape has an infinite energy. Also, side group–scaﬀold and side group–side
group bump checks were included to ensure that the designed molecules are
not self-intersecting.
2.5 Scaﬀold search and placement
An examination of the current literature and candidate inhibitors in clinical
trials suggested that ketoamides were an eﬃcient compound class that
inhibits HCV protease [69]. The carbonyl carbon of the ketoamide keto
group participates in covalent bond formation with the substrate while the
amide carbonyl group actively engages in the oxyanion hole interaction.
The 1,3,5-triazine structure was considered as part of the ligand scaﬀold
structure. A triazine core can introduce significant diversity in compound
synthesis [70] and previous work in the Chang lab promise possible synthesis
of a large number of potential compounds [71]. Furthermore, the 1,3,5
triazine core with one of it three positions (2,4,6) that can be attached
with the necessary functional group (ketoamides) used as inhibitors for
serine proteases has been previously reported [72]. Chemical catalogs were
searched to identify ketoamides with functional groups that could be used
for attachment to the triazine core. Because very few such groups were
found, a mechanism (Figure 2.13) was devised to synthesize the ketoamide
functional group from a simple ketoacid that can be attached to the triazine.
The synthetic scheme for the molecules based on this triazine structure
requires primary or secondary amines to functionalize two positions (out of
2, 4, and 6); the third position is functionalized by the di-keto containing
building block that is reacted with a primary or secondary amine to produce
the keto-amide functional group (Figure 2.13). A lab tested database of








































Figure 2.11: Ketoamide inhibition mechanism. One of the carbonyl groups is
involved in bond formation with the catalytic serine, and the other carbonyl







Figure 2.12: Triazine core; R : −NH −R￿ ,−O −R￿ ,−S −R￿
designed can be found in Figure 2.1c.
Figure 2.13: Reaction showing the synthesis of ketoamides from the ketoacid.
2.5.1 Scaﬀold preparation and ensemble generation
The preparation of the scaﬀold began with obtaining a 3D structure. The
scaﬀold structure with its attachment points replaced with hydrogen was
written in as a SMILES [74] file, a text format representing structures of
chemical entity. Since the covalently bound form of the scaﬀold is considered,
the carbon that forms the covalent bond is given a tetrahedral geometry
with a dummy hydrogen mimicking the serine hydroxyl oxygen. The file
was geometry optimized using OPEN BABEL software [75] as an initial
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treatment. This reasonably optimized structure obtained by steepest descent
algorithm that finds the local minima, is then geometry optimized using
Gaussian 03 [76] at RHF/6-31G* level of theory. Following which the partial
atomic charges are determined writing the potential points and potentials
using RESP method [77, 78]. Following the optimization and RESP fitting,
the scaﬀold was labelled at the points of attachment.
The scaﬀold was aligned with the transition state substrate at the
tetrahedral carbon that engages in covalent binding and atoms attached
to it using VMD software [62]. The scaﬀold ensemble was generated by
torsional sampling. Because of covalent binding, there is no translational
freedom of the scaﬀold and the conformations were generated by rotating
each rotational bond in 30◦ increments starting from 0◦ to 360◦. The
positions that stayed within the envelope without van der Waals clash were
considered and the scaﬀold conformations that could extend on all three
sides with at least an amine group were retained.
Scaffold ensemb e 
• rot 1, 2 - whole scaffold is rotated
• rot 3     - rotates C1, O2, H along axis C1-
C3
• rot 4     - rotates C5, O6, Tz(Triazine) along 
axis C5-C3
• rot 5     - rotates O6, Tz along axis O6-C5
• rot 6     - rotates Tz along axis Tz-O6








Figure 2.14: The rotatable bonds when the scaﬀold is attached to catalytic
ser 139 were rotated 360◦ in steps to generate the scaﬀold conformers.
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2.6 Side group library preparation
A lab tested database of 676 primary and secondary amines were consid-
ered. The stereochemistry was preserved and prepared using the LIGPREP
software [79]. The preparation included hydrogen treatment followed by
desalting. The ionization states of the molecules were included since in
vivo, the compounds can exist in the ionized state and could make better
interaction with the protease compared to a molecule that makes excellent
interaction in its unionized state, and the tautomers were generated. Each
of these ligprep steps were individually tested and optimized instead of
using the default option so that none of the possible structure/conformation
is missed. Finally the in-built minimizing option was used to optimize
the structure to have a good starting structure for Gaussian [76] optimiza-
tion. Following which Gaussian [76] RHF/6-31G* level of theory was used
to get the geometry optimized structures from the reasonably optimized
structures. The partial charges were then fitted using the RESP method
[77, 78]. Since the triazine and the di-keto group induce a planar geometry
for the side groups at the amine group, the planar geometry was forced to
all the side groups at the amine nitrogen using rotation matrices and the
necessary changes were included to change the atom type upon attachment.
Finally the rotamer library was generated by torsional sampling based on
hybridization of the bonded atoms (30◦ for sp3 − sp3 and sp2 − sp3, and
45◦ for sp2 − sp2).
2.7 Pairwise decomposition of the scoring
function considering conformational change
The inverse design procedure uses DEE and A* algorithms to search and
rank the global optimal and progressively sub-optimal structures. The side
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groups attached to the scaﬀold are enumerated discretely making the scoring
function pairwise decomposable. Considering a conformation change in the
scaﬀold after binding, the total energy of a given scaﬀold with added side
groups would satisfy,










n is the number of attached discrete side groups.
Econst represents constant energy terms in the form of Equation (2.3).
The constant energy terms include the grid based van der Waals and
electrostatic binding free energy of the blunt scaﬀold (scaﬀold with the the
growable hydrogens removed), and the receptor desolvation penalty that
remains constant throughout the search. It is written as,






where qscab,blunt and qscaub,blunt are the grid projected partial atomic
charges of the blunt bound and unbound state scaﬀold respectively with
Sb, Sub, ￿C, and Rdes derived from the electrostatic grid calculations.
Eself is the self energy for each side group conformation. The self energy
term includes the grid van der Waals energy and electrostatic binding
energy for the side group, as well as the indirect electrostatic interaction
contribution between the scaﬀold and the side group. Here again the
growable hydrogen and the attachment point hydrogen in the side group
are removed and the charges from the scaﬀold growable hydrogen is added
to the antecedent atom in the side group and vice versa to ensure charge
conservation.
Eselfi = vdWsg,blunt + (￿q
T
sg,bluntSb￿qsg,blunt − ￿qTsg,bluntSub￿qsg,blunt)
+(￿qTsg,bluntSb￿qscab,blunt − ￿qTsg,bluntSub￿qscaub,blunt) + ￿qTsg,blunt ￿C (2.6)
Epair is the pair energy for each pair of side group conformations consid-




 ∞, if functional group bump￿qTsgi,bluntSb￿qsgj ,blunt − ￿qTsgi,bluntSub￿qsgj ,blunt, otherwise(2.7)
A pair that fails bump check and is found to clash with one another
is given infinite energy and are eliminated from consideration in inverse
design.
Note that in each of the calculations above, the desolvation term is
computed from the bound and unbound solvation matrices. When there is
no conformational change, coulombic terms cancel upon taking the diﬀerence
between bound and unbound states.
2.7.1 Functional group attachment and pairwise en-
ergy evaluation
The following was done for the non-rigid binding implementation starting
from creating an unbound scaﬀold from each bound scaﬀold conformation.
Then, as a first step in computing the pairwise energies for all side groups,
all growable hydrogen atoms were removed from the unbound and bound
scaﬀold. The respective blunt scaﬀolds (bound and unbound) without the
growable hydrogens remained constant throughout the search for every
scaﬀold conformation considered. A scaﬀold conformation is considered
only if both the bound as well as the unbound scaﬀold conformation stayed
within their respective envelopes. The van der Waals and electrostatic
grid-based energies were computed for the blunt scaﬀold and stored along
with the precomputed receptor desolvation Rdes as the constant term in
the pairwise energy decomposition shown in Equation 2.4. The desolvation
was computed by subtracting the unbound solvation energy from the bound
solvation energy. The bound solvation energy is calculated by projecting the
bound blunt scaﬀold’s partial charges and similarly the unbound solvation
energy is calculated from the unbound blunt scaﬀold.
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The side groups were attached to each growable site in the scaﬀold by
removing the attachment hydrogen and creating a single bond between
the two blunt atoms along the same vector used by the scaﬀold hydrogen.
The bond length was set to the equilibrium value from the CHARMm22
parameter set. Rotations were generated about the newly formed bond
with the same hybridization-based rules used for conformational sampling.
Newly attached side groups were examined to ensure that all atom centers
were no closer than 0.5 A˚ to the target shape surface, and that the side
group did not intersect the blunt scaﬀold when 75% van der Waals radii
were used. If a discrete functional group failed one of these checks, it was
removed from consideration in the rest of the search procedure. When the
attachment hydrogens are removed from the scaﬀold, their partial charges are
exchangeably added to the antecedent atom (i.e, the attachment hydrogen
charge from the scaﬀold was added to the side group antecedent atom and
vice versa). This was done to preserve the integral charge and account
for the inductive eﬀect. The grid-based van der Waals and electrostatic
energy of the blunt functional group, as well as the indirect desolvation
between the functional group and the blunt scaﬀold were then computed
using Equation 2.6 to generate the self-energy terms. The pairwise energy
calculation was done to compute the pair contributions to binding (that is
the indirect desolvation terms between each pair of side groups). Again,
here the desolvation was computed using the bound and unbound solvation
matrices and an infinite energy was given if any two side groups clashed
when 75% van der Waals radii were used (Equation 2.7). The attachment
hydrogen was eliminated when considering for bump check.
A similar protocol was followed for the rigid binding except that in
the rigid binding, the unbound and bound scaﬀolds considered were same
and the desolvation matrix was computed directly rather than considering
bound and unbound solvation matrices. The change was included to do
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the design considering the conformational change in both the receptor and
ligands.
2.8 Computational inverse inhibitor design
Single and pair-wise energies were computed by placing the bound and
the unbound scaﬀold positions in their respective substrate envelope and
attaching the side groups at corresponding positions. Because these energies
were pairwise additive, guaranteed DEE and A* algorithms were employed
to search and rank the best energy binders. The top scoring compounds
from the low resolution design were then re-evaluated using higher resolution
energy functions that include explicit van der Waals interactions, continuum
electrostatic calculations given accurate shape of the molecules, and a
non-polar solvation term proportional to the solvent accessible surface area.
2.8.1 Design considering the conformational change
The unbound structure was constructed for each scaﬀold position by adding
partial charges from the geometry optimized and charge fitted non-covalently
bound scaﬀold, and by changing the coordinate of the oxyanion to that of
the carbon atom that covalently binds to the catalytic serine. Because the
keto group carbonyl carbon and oxygen atoms were overlaid, the charges of
those atoms where changed to satisfy the dipole moment without disrupting
the monopole. If the dipole charges are brought closer with a distance of only
0.1 A˚ between them, charges of approximately +5e and −5e are required
to equal the dipole moment due to charges (+0.4e and −0.4e) separated
by 1.2 A˚. So a charge of +5e and −5e were added to the carbonyl carbon
and oxygen respectively in their unbound structures. For each scaﬀold
position, the prepared side groups were attached, and single and pairwise
energies were computed. The desolvation computation was performed
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using the bound and unbound solvation potentials. Locally implemented
DEE [50, 52, 51] and A* [53] algorithms that includes several algorithmic
enhancements [80, 81, 82, 83] were used to search and rank the global
optimal and sub-optimal structures. After finding the GMEC, ranked list of
configurations were computed in steps of 2.5 kcal ·mol−1 increments until
the list had 1000 conformations of 100 unique molecules or a maximum of
20 kcal·mol−1 was reached.
2.8.2 Hierarchical re-scoring of top structures
The grid-based design has deficiencies that can be corrected by re-evaluating
the top scoring compounds using increasingly better energy functions. One
of the deficiency of grid-based calculations are that it uses fixed target shapes
for bound and unbound state ligands. The other important deficiency is
the change in coulombic interaction that plays a part when there is a
conformational change in the receptor and/or ligand conformation after
binding. This term will be zero when considering rigid binding. The method
using higher accuracy energy functions to correct the deficiencies of the grid-
based approximations involved solving the linearized Poisson–Boltzmann
equation for the whole molecule with its exact shape, to get the electrostatic
component. The devised thermodynamic process for non-rigid binding was
followed. In addition the solvent accessible surface area term was included
to get the hydrophobic component.
The molecules were re-scored in two steps using a Poisson–Boltzmann /
Surface Area model [68]. Here the carbonyl group that was altered for the
low resolution calculation was minimized using CHARMM and given the
proper geometry. The molecule shape correction was provided and explicit
van der Waals energies were computed. The hydrophobic contribution
was included by computing the Solvent Accessible Surface Area using a
probe radius of 1.4 A˚ and a scaling factor of 5 cal . A˚−2. The solvation
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calculation in bound and unbound state was computed using a locally
modified version of DelPhi [59, 60] using a 65× 65× 65 grid resolution for
the medium resolution calculation and 129× 129× 129 grid resolution for
the high resolution with focusing boundary conditions [84]. PARSE radii
[68] were assigned to the ligand. The conformational energy defined as
￿Gconf = ￿Gcoulomb +￿Gdihe +￿Gimpr
where,
￿Gcoulomb is the change in coulombic interaction between the bound
and unbound conformation.
￿Gdihe is the change in dihedral energy.
￿Gimpr is the change in impropers.
was computed using CHARMM with constant dielectric of 4, and added
to account for the shape change and accuracy.
47
Chapter 3
Design results and Analysis of
designed inhibitors
The implemented inverse design methodology with conformational change
was applied to obtain robust inhibitors for the HCV NS3/4A protease.
Hierarchical re-scoring was done to overcome the approximations and obtain
the top scoring compounds, after which the compounds were computa-
tionally analyzed to evaluate their robustness in comparison to a small
collection of commercial and candidate inhibitors. This chapter presents
the results generated from the combinatorial search, their re-scoring using
more accurate energy functions, and computational analysis to evaluate
their robustness by comparison with known compounds for which there are
available experimental results.
3.1 Validation of non-rigid binding design
implementation
The simplest way to evaluate the implementation was to do a rigid binding
design with the non-rigid implementation and compare its result with the
result of the rigid implementation that we already have. The HCV NS3/4A
system was considered for the validation.
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3.1.1 Protein preparation, substrate envelope construc-
tion and grid-based potentials
The protein preparation and substrate envelope construction follows the
procedure described in chapter 2. Briefly, the substrate was modeled adding
the four essential residues and the substrate envelope was prepared from
the 6 ns molecular dynamics simulation with snap shots of the substrate in
the binding site saved every 200 fs. The associated bound state structure
described in chapter 2 (section 2.2.2) represents rigid binding. Hence
the unbound envelope constructed in chapter 2 (section 2.3.1) represent
the bound and unbound state envelope in both the rigid and non-rigid
implementation. Grid-based calculations were performed using the rigid
and non-rigid implementation. The rigid implementation using the two step
thermodynamic process (section 2.4.1) computes the desolvation potentials
directly. The non-rigid implementation computes the bound and unbound
solvation potentials using the newly developed thermodynamic process
(section 2.4.1) that has the capability to handle conformational changes.
3.1.2 Side group preparation
The side group preparations follows the same procedure described in chapter
2 (section 2.6). The side groups considered for validation included 7 amines
of various sizes from 676 amines described in chapter 2 (section 2.6). The
rotamer library was not generated for validation. Briefly, the initial prepa-
ration of the side groups included chirality preservation, adding hydrogens,
removing salt molecules from the side groups in the database, and generat-
ing tautomers and obtaining molecules in their ionized as well as neutral
state using LIGPREP software [79]. The molecules were given reasonable
geometry optimized structures by energy minimization using LIGPREP
software [79]. Then quantum mechanical geometry optimization was done
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using GAUSSIAN 03 at the RHF/6-31G* level of theory, following which
the partial charges were fitted to the potential using the RESP method
[77, 78]. Since the amines attach to the triazine or di-keto group with a
planar conformation, all the side groups were given a planar configuration
using rotation matrices at the amine attachment point.
3.1.3 Scaﬀold library preparation
The scaﬀold library preparations follows the procedure described in chapter 2
(section 2.5.1). The scaﬀold (Figure 2.1c) was considered without providing
the tetrahedral geometry for the di-keto carbon. The scaﬀold was built
giving the molecular formula in SMILES [74] format and geometry optimized
using steepest descent using OPENBABEL [75] . The molecule was then
subjected to quantum mechanical geometry optimization using GAUSSIAN
03 [76] at the RHF/6-31G* level of theory. The RESP method was used to
fit partial atomic charges to the electrostatic potential.
3.1.4 Scaﬀold placement and design
The prepared scaﬀold was aligned with the substrate at the keto group using
PROFIT [85]. Then the scaﬀold was placed in the binding site, and sampled
with a translational enumeration for 10 layers in steps of 0.25A˚ and by
rotating the molecule. For each translation along the X, Y or Z coordinates,
the molecule was rotated in steps of 30◦ with internal rotations of 10◦. The
scaﬀold positions were checked to remain within the fixed target shape with
a distance of at least 0.5 A˚ away from boundary. This boundary padding
was necessary to ensure that the partial atomic charges were not spread to
grid points outside the fixed shape. The obtained scaﬀold conformations
were tested and checked for conformations that could grow the side groups
on all three positions with a test library containing amines ranging from the
smallest to the largest in size. The positions that failed this check and/or
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had unfavorable van der Waals energy were rejected. With the scaﬀold and
side groups ready, the design was carried out using both implementations.
3.1.5 Combinatorial search, hierarchical re-scoring and
results
The global minimum binding energy configuration (GMEC) and progres-
sively sub-optimal binding energy configurations were determined for each
scaﬀold placement using a locally developed implementation of DEE and
A* algorithms. After determining the GMEC, a ranked list of configura-
tions was computed in steps of 2.5 kcal ·mol−1 until the list contained 10
conformations of 10 unique molecules or a maximum of 10 kcal · mol−1
was reached. Ligands were considered ”unique” if they diﬀered in their
functional group attachment pattern, and not solely in conformation. These
best 100 (10× 10) structures were pooled across all scaﬀold placements,
sorted on total energy, and the top ten thousand structures were stored.
Identical parameters were considered for both the implementations.
The design results generated were compared, plotting the energies against
each other to check if the individual energies and the total binding energies
perfectly correlate. The correlation plots are shown in Figure 3.1. Of the
8223 molecules generated, the top 300 were picked and a perfect match
was observed (R2 ≈ 1) between the two approaches in individual and total
energies. This shows that both these methods work exactly the same
when rigid binding is considered, thus serving as a minimal check of the
implementation.
Next the hierarchical re-scoring method for the non-rigid binding imple-
mentation was validated the same way. The top 300 of the 8223 molecules
were analyzed using the linearized Poisson–Boltzmann solvation model using
the exact shape for the molecules. In the existing code the desolvation
was directly computed solving the linearized Poisson–Boltzmann equation,
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low Resolution Binding Electrostatics






































high Resolution Binding Electrostatics
Figure 3.1: Low and high resolution validation. Top panel shows Lowres
electrostatic binding energy plotted. Bottom panel shows Highres electro-
static binding energy plotted. Figure shows that the electrostatic energy
terms match well in both implementations - green: ligand desolvation; blue:
receptor desolvation; black: electrostatic interaction.
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whereas in the non-rigid binding implementation, the solvation energies in
the bound and unbound states were calculated and desolvation was com-
puted by finding the diﬀerence between them as described in the previous
section. Explicit-atom van der Waals packing energies were computed as
an improvement to grid-based energies, and the hydrophobic contribution
to solvation was computed as directly proportional to the solvent accessible
surface area buried upon binding, using a probe radius of 1.4 A˚ and a scaling
factor of 5 cal . A˚−2. The solvation free energy in the unbound state and the
bound state was computed with a locally modified version of DelPhi [59, 60]
using a 129× 129× 129 grid and PARSE radii [68] assigned to the ligand.
Parse charges were used for the receptor while charges on the designed
molecules were kept the same as those used in the combinatorial search
which is quantum mechanically derived. Vacuum electrostatic interactions
used a constant dielectric constant of 4. In addition the non-rigid binding
implementation computed the change in conformational energy ￿Gconf ,
to account for the conformational change as explained in the Figure 2.10.
Then the correlation was plotted to compare the implementations. The
￿Gconf term when considering the rigid binding was zero, as it should
be. All the energy terms and total energy match to perfection (R2 ≈ 1),
indicating that both implementations behave in a similar fashion if rigid
binding is considered. The symmetric outliers seen are due to functional
group indexing errors, which was checked by visualizing molecules with
large energy variation.
3.2 Combinatorial search results and hierar-
chical rescoring
A maximum of 500,000 molecules was set as limit, and the global opti-
mum and sub-obtimal structures were obtained from the combinatorial
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search (low resolution design). Then hierarchical re-scoring was done doing
MM/PBSA calculations at lower grid resolution of 65× 65× 65 (medium
resolution design) for the complete 500,000 molecules. The energies where
plotted to check for correlation. The van der Waals grid calculations done
had the receptor catalytic serine’s side chain removed to avoid inaccurate
computation of energies due to clash. This was corrected when re-scoring
doing an explicit van der Waals energy computation. The plot revealed that
the van der Waals energy in the low resolution design and medium resolution
design correlated (Figure: 3.2a). The electrostatic calculation (Figure: 3.2b)
showed that the interaction energy correlated in low resolution and medium
resolution design. One of the assumptions considered in the low resolution
design that was corrected in the medium resolution design was the fixed
shape assumed for the bound and unbound state of the ligand. In medium
resolution design the assumption was corrected providing the exact shape
for each ligand considered. We attribute the negative desolvation value to
the covalent bond and the approximate unbound ligand shape designed from
the bound shape. The receptor desolvation is a vertical line because due to
the fixed shape assumed the low resolution design will have a constant value
for receptor desolvation and it was found to be corrected in the re-scoring.
Hence the desolvation plots were not to find correlation rather to check
how the molecules perform with the corrections. The total energy plot
helps us to infer more from the result. The total energy correlation plot
(Figure: 3.3a) showed a strong upward slope. The medium resolution design
is to correct the assumptions and deficiencies of the low resolution design,
and the low resolution combinatorial search is a necessary way to get the
global minimum and sub-optimal structures. Hence we are not interested in
getting the correlation between the lower resolution and medium resolution
design, rather the upward slope that provides confidence in filtering the
top scoring molecules. The upward slope indicates that no molecules that
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scores poorly in the low resolution performs better in the medium resolution.
Since it is computationally expensive to consider all the molecules obtained
from low resolution design for high resolution design, medium resolution
becomes a necessary step to obtain reasonable number of compounds that
has potential to perform well.
After confirming that the design yielded good compounds that performed
well in both low resolution and medium resolution design, the deficiency that
could not be added in the low resolution design – the conformational energy
￿Gconf was added to medium resolution design to find top scoring molecules
with relatively accurate energy values. The total energy correlation plot with
￿Gconf added to the medium resolution design is shown in Figure: 3.3b, and
the molecules that had energy ≤ to− 35 kcal ·mol−1 were evaluated with
the MM/PBSA calculations at higher grid resolution of 129× 129× 129
(high resolution design). This showed a highly correlating result with sharp
upward slope. The plots can be seen in Figure 3.4 and 3.5. The shift in total
energy was found to be due to the added ￿Gconf . Both medium resolution
and high resolution results were plotted with ￿Gconf . The scaﬀold also
takes up an inverted conformation depending on the direction from which
the carbonyl carbon is attacked by serine 139, where the carbonyl carbon
that involves in bonding with the receptor and the oxygen attached to it
exchange positions. Designs were carried out sampling this conformation
(data not shown). But this conformation yielded molecules with relatively
bad van der Waals energy. The up-slope was observed but the molecules
did not have better binding energy and hence were not further considered.
With the high resolution design refinement, the top molecules with ener-
gies ≤ to− 48 kcal ·mol−1 was selected for further analysis. The preferred
side groups and their frequency of occurrence was analyzed. A sample
inhibitor designed is shown with the attachment points in Figure 3.6. Fig-












































































































































































































































































































































































































Figure 3.5: Plot between medium and high resolution total energy. The red
line indicates y=x. The shift in the total energy is due to the addition of
￿Gconf .
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functional group in the figure appears in more than 10% of the designs.
Analysis showed that the R1 group with a carbonyl oxygen could interact
with lysine 136 and with a hydroxyl group instead of carbonyl could interact
with the inhibitor’s oxyanion. Since the binding site is solvent exposed, even
hydrophobic groups were preferred. The most preferred R2 group is often a
ring structure functionalized with an exocyclic oxygen. The ring structure
engages in sulphur-π interactions. The oxygen hydrogen bonds with the
cysteine 157 backbone NH. The other groups at R2 in the high resolution
design are that mainly contains cyclic groups (penta, hexa, hepta homo
and hetero cyclic – Pyrrolidine, Piperidine; aromatic) or linear hydrophobic
groups. The R3 group prefers a hydrophobic fork-like structure with open
ends, or 4 or 5 membered cyclic structures. The other functional groups
in the high resolution design at R3 position includes tri, penta and hexa
cyclic compounds and linear hydrophobic groups. The highly prefered side
groups and their interactions with specific residues infer potential strong
interactions possible at the active site of HCV Ns3/4A protease that respects
substrate envelope. Being a solvent exposed active site, a lot of hydrophobic
groups were preferred highlighting the eﬃciency of the design.
3.3 Computational analysis of designed in-
hibitors for HCV NS3/4A protease
Computational analysis can prove to be very useful to predict the perfor-
mance of designed compounds particularly their aﬃnity to mutant targets.
Comparing the binding energies of the designed inhibitors with that of
current clinical candidates whose resistance profiles have been studied could
provide useful insights about our designed inhibitors. The information about
change in binding energies due to mutations could tell us how the designed





Figure 3.6: Designed inhibitor fits inside the substrate envelope and makes










































































































































































































































































































































































































Figure 3.7: Preferred side groups at the attachment points, labelled with
the number of times they occurred in the 2020 tightest binding designed
molecules. The atom ”D” represents the point of attachment to the scaﬀold.
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resistance mutations. Also, this analysis could act as a filter to pick best
performing compounds in terms of binding energy which remain robust even
in the presence of a mutation.
3.3.1 Current inhibitors, substrate envelope and re-
sistance mutations
The resistance mutations in NS3/4A protease occur around the active site
in regions where drugs protrude the substrate binding envelope, and the
protruding groups are found to interact with these residues that confer
resistance to the inhibitors upon mutation [46]. As the substrate envelope
hypothesis posits, these changes can disrupt inhibitor binding with minimal
eﬀect on the substrate, thus letting the viral protease continue with its
function. The macrocyclic inhibitors are found to have large P2 moieties
that bind in the S2 subsite and make extensive interaction with residues
arginine 155, alanine 156 and aspartate 168 [46]. A clear π-cation stacking
associated with induced binding is apparent. This change in conformation
with arginine 155 is supported by salt bridge formation with aspartate 168
and arginine 123, and hydrogen bonding with glutamine 80. The resistance
conferred by mutation of either arginine 155 or aspartate 168 is attributed
to loss of interaction with these specified resistance-prone residues while
the variation in the eﬀect of resistance is attributed to the above-mentioned
disturbed electrostatic network and its eﬀect on other groups present in
the inhibitor. Alanine 156 placed at the active site, provides a limited
interaction with the substrate with two backbone hydrogen bonds (Figure
3.10a). When mutated to residues like threonine or valine, A156 could
pierces the substrate envelope, severely aﬀecting inhibitor binding provided
the inhibitor made significant interaction with A156. The resulting van der
Waals clash suggests that inclusion of substrate dynamics with modeled
mutations could serve as a refinement for substrate envelope generation.
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Protrusion of substrate envelope along with crystal structures of inhibitor-
bound wild-type and mutant protease structures has been reported [41, 46].
In this section, we intend to test and compare our designed inhibitors with
some potential clinical candidates (ITMN-191, TMC-435) and commercial
inhibitor (boceprevir) by analyzing and comparing their binding energies,
and by performing mutational analysis modeling the discussed mutations of
R155 and A156.
Figure 3.8: Current inhibitors under development or in the clinic (TMC-435,
yellow; ITMN-191, magenta; Boceprevir, green). All protrude from the
substrate envelope. By contrast, our designed inhibitors (one of which is
shown in cyan) fits within the substrate envelope. Inhibitors that bind




Two types of comparisons were performed — one with the wild type-
inhibitor/substrate bound structures (substrate - 1CU1 [58]; Boceprevir -
2OC8 [38]; TMC-435 - 3KEE [40]; ITMN-191 - 3M5L [41]) to analyze their
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binding energies, and the other with inhibitor/substrate structures with
modeled mutations to compute the expected behavior of the inhibitors in the
presence of the resistance mutations. To make a uniform comparison, all the
structures were made to have the same residues contained in the substrate-
bound structure. The sequence was trimmed/expanded for individual
structures so that the important sequence length was maintained and at the
same time the structures were symmetrical. All crystal waters were removed.
In the first case, except for the generated residues or atoms, all others were
kept fixed during preparation. In case two, since the mutation was modeled,
the residue considered for mutation and associated residues that were known
to interact with the residue to be mutated were kept flexible along with the
generated residues/atoms. In both the cases, for the unbound structure,
the respective bound state structure was considered. The catalytic serine
kept flexible during preparation if the inhibitor/substrate engage in covalent
bonding.
The protein structure that was used for the design was kept as the
wild-type structure and the rest of the considered protein structures were
made to contain the same residues. The residues that were changed had
their side chain removed and the necessary residues were modeled during
the preparation. Each structure was individually checked for flip states
of asparagine, glutamine and histidine and the end of the rotational bond
was rotated 180◦ if it made better hydrogen bondings. Also the histidines
were given proper protonation states by manual checking . The wild-type
had side-chains of asparagine 49, glutamine 28, histidine 57 and glutamine
526 of helicase residue set flipped and had histidine 57 delta protonated in
its unbound state. Similarly for structure with boceprevir bound, the side
chain of glutamine 34 was flipped and had histidine 57 delta protonated
in the unbound state. The bound state of the wild-type receptor and
beceprevir bound protease had histidine doubly protonated to account for
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proton abstraction from serine 139. The TMC-435 bound receptor had
asparagine 27 and glutamine 9, 28 and 34 flipped and ITMN-191 bound
receptor had asparagine 27 and 47, glutamine 9 and 34 and histidine 110
flipped with histidine 57 delta protonated in both the cases. The protein
ends were made peptide-like by providing the acetyl and N-methylamide
blocking groups to the N-terminus and C-terminus, respectively. In case of
the receptor-substrate, receptor-designed inhibitors, and for the boceprevir
bound complex, a patches was applied to create the covalent bond between
the receptor serine and the ligand. Note that the substrate bound protein
was used for the designed inhibitors. For the unbound state of macrocyclic
non-covalent inhibitor-bound proteins the arginine 155 coordinates were
changed to the one from the unbound structure (3KF2 [40]), as the induced
binding can be clearly visualized. The hydrogen atom positions were built
using the HBUILD [63] functionality in the CHARMM computer program
[64], using distance dependent dielectric constant of 4r.
Inhibitor preparation
The inhibitors were prepared by adding hydrogens and adding charges. The
inhibitor in the same conformation is considered for both the bound and
unbound state in case of the macrocyclic inhibitors, and in the case of
linear inhibitors where the inhibitors go for covalent bonding, unbound
structure was generated from the bound structure as prepared for the
medium and high resolution design presented in Chapter 2 (section 2.8.2)
by energy minimizing the carbonyl group. The designed inhibitors were
considered as prepared in chapter 2 (section 2.6). The other inhibitors
were prepared by adding hydrogens to the ligand conformation obtained
from the experimental ligand bound HCV NS3/4A protease structure using
OPEN BABEL software [75]. The potentials were generated for the ligand
conformation using quantum mechanics (GAUSSIAN 03 [76]). The charges
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were then fitted using RESP method [77, 78]. In addition to the procedure
described above, the attachment carbon was given a tetrahedral shape
adding a hydrogen in the place of the catalytic serine 139 hydroxyl oxygen
for the boceprevir and substrate preparation. The charge on the attachment
carbon was adjusted to satisfy the total charge when attached to the
receptor.
Molecular mechanics / nonrigid-binding Poisson–Boltzmann sur-
face area calculation
The molecular mechanics / nonrigid-binding Poisson–Boltzmann surface
area was used as the energy function to do the analysis. It computes the
binding energy with the direct van der Waals interaction, electrostatic
solvation and interaction, nonpolar solvation term and self energy terms to
account for the conformation free energy (￿Gconf ) due to nonrigid-binding.
The procedure and parameters used are the same as in the high resolution
calculation discussed in chapter 2 (section 2.8.2).
3.3.3 Comparison to known inhibitors
Molecular mechanics / nonrigid-binding Poisson–Boltzmann Surface Area
analysis of the wild-type structures (Figure 3.9) showed that boceprevir had
the lowest receptor desolvation penalty of −1.44 kcal ·mol−1. The designed
inhibitors had receptor desolvation range of 3.644 kcal ·mol−1 to 11.078 kcal ·
mol−1 and the substrate had receptor desolvation of 6.20 kcal ·mol−1. The
TMC-435 had the worst receptor desolvation of 19.29 kcal ·mol−1 followed
by ITMN-191 that has penalty of 12.48 kcal ·mol−1. The designed inhibitors
performed the best in ligand desolvation having values ranging between
−3.247 kcal ·mol−1 to 2.642 kcal ·mol−1. The negative desolvation values are
attributed to covalent bonding. Both the substrate as well as the boceprevir
did well with 2.74 kcal ·mol−1 and 2.08 kcal ·mol−1 respectively. ITMN-191
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had 7.808 kcal ·mol−1 and TMC-435 had a value of 8.434 kcal ·mol−1. The
solvent-accessible surface areas (SASA) were similar with TMC-435, ITMN-
191, boceprevir, substrate having a value of −6.391 kcal·mol−1, −3.735 kcal·
mol−1, −5.210 kcal ·mol−1, −4.473 kcal ·mol−1 respectively and designed
inhibitors having a range between −4.139 kcal ·mol−1 to −3.254 kcal ·mol−1.
The electrostatic interaction of the designed inhibitors (−26.02 kcal·mol−1 to
−16.432 kcal·mol−1) and the substrate (−23.758 kcal·mol−1) were favorable
compared to the existing inhibitors (boceprevir: −16.405 kcal·mol−1; ITMN-
191: −10.362 kcal · mol−1; TMC-435: −13.756 kcal · mol−1). The van der
Waal’s energy was very favorable for the macrocyclic inhibitor TMC-435
(−67.561 kcal ·mol−1). But compared to the other inhibitors (boceprevir:
0.14 kcal ·mol−1; ITMN-191: −18.647 kcal ·mol−1), the designed inhibitors
(−40.615 kcal·mol−1 to −27.17 kcal·mol−1) performed better. The substrate
had a van der Waal’s energy of −37.129 kcal ·mol−1. Overall the TMC-435
performed better in binding energy calculations due to its excellent van der
Waals energy and interestingly the designed inhibitors behaved more like
the substrate in both individual energy terms and overall, which is a good
sign considering design including the substrate envelope hypothesis. This
analysis showed that the substrate envelope helped the designed inhibitors
to capture essential substrate interactions and avoided interactions that
would violate the substrate shape.
3.3.4 Expected behavior with known mutants
We chose to explore two prevalent mutations namely the arginine 155 and
alanine 156 to validate the substrate envelope hypothesis. The goal was to
make the comparison without altering the crystal coordinates unless it is
absolutely necessary. Since the mutations could alter some known specific
residues to make better interaction, for this analysis the residues arginine






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































proteins were prepared. The R155K and R155T calculations clearly showed
the pattern in which they are aﬀected as we found in the experiments (Table
1.1) reported in [47] i.e, in both the macrocyclic inhibitors R155K (TMC-
435: 13.228 kcal ·mol−1; ITMN-191: 11.96 kcal ·mol−1) was associated with
greater loss in activity compared to R155T (TMC-435: 10.316 kcal ·mol−1;
ITMN-191: 5.704 kcal ·mol−1) while the calculation clearly revealed in case
of boceprevir that R155T (1.695 kcal ·mol−1) was associated with greater
activity loss compared to R155K (1.227 kcal · mol−1) (Figure 3.12). The
analysis also showed that the designed inhibitors remained the same with
minimal eﬀect ( losing only 0.262 kcal ·mol−1 to 0.62 kcal ·mol−1 in case of
R155K and performing −0.8510 kcal ·mol−1 to −0.4850 kcal ·mol−1 better
in case of R155T). Although boceprevir was slightly more aﬀected than
the designed inhibitors, this linear ketoamide inhibitor handled the R155
mutation much better than the macro cyclic inhibitor as was reported in
[87]. We expected this as we could clearly see that the R155 made very
good stacking interaction with the inhibitor and it protruded the substrate
envelope at that position. Boceprevir, though found closer to R155, did
not protrude the envelope around that region. The results established the
same. The exact correlation with the experimental results in case of current
inhibitors may not be achieved due to the approximations considered – the
covalent bonding, the approximate unbound inhibitor structure considered
and the geometry and position of the wild type inhibitor considered even
when mutations were modeled. But nevertheless, our computational analysis
reflected the experimental results and validates the experimental claims.
The A156V and A156T mutation established the pattern showing that
in all the inhibitors, A156V is associated with greater activity loss compared
to A156T (Figure 3.12).The inhibitors Boceprevir, TMC-435 and ITMN-
191 showed an aﬃnity loss of 10.825 kcal · mol−1, 5.594 kcal · mol−1 and

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































mol−1, 33.567 kcal · mol−1 and 34.536 kcal · mol−1 in case of A156V. The
designed inhibitors though did not show a flat profile as in R155 study,
showed that it was minimally aﬀected with losing only a maximum of
4.925 kcal · mol−1 for A156T and 11.576 kcal · mol−1 for A156V. Alanine
156 mutation aﬀects ligand binding mainly through van der Waals clash.
Again as reported in [87], the linear ketoamide inhibitors were found to be
aﬀected more due to A156 mutation compared to R155. Further boceprevir,
ITMN-191 were found to protrude the envelope at A156 position. Models
showed that the A156 mutations had their side chains close to the envelope
or protruding it.
The compounds with flat resistance profile were filtered and analyzed
for functional groups. From the 269 unique molecules, the compounds that
lost only 2 kcal · mol−1 were picked. This yielded 72 compounds whose
respective functional groups are shown in Figure 3.13. The analysis showed
that the best compounds that had a flat binding profile included the keto-
oxolane and an alcohol functional group in the R1 position. Interestingly,
the groups were among the highly preferred functional groups in the high
resolution design. The R2 position included a diverse set of functional
groups including one that was highly preferred in the high resolution design.
The R3 preferred a tri, quadro and penta cyclic functional group with one
common functional group in the highly preﬀered functional group list of the
high resolution design. These generated compounds were shown to handle
resistance mutations exceptionally well in the computational analysis.
In summary, the non-rigid implementation work accurately. The design
results suggested 12 compounds (Figure 3.7) that have the potential to in-
hibit HCV NS3/4A protease as well as handle resistance mutations. Further
analysis of the high resolution design results showed that all the designed
compounds captured substrate-type interactions following a substrate-type
breakdown of binding energy terms. Mutational analysis validated the ex-
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perimental claims using some potential clinical candidates and commercial
inhibitors and showed that the designed inhibitors indeed have the potential




Drug design — still considered to be in its infancy by many, is challenging
due to several reasons. Obtaining a lead compound and making it available
for public is a multi stage process that has a very high probability of failure.
But the major obstacle in the use of the drug in clinic arises due to drug
resistance [1]. The prevalent way to handle this is to study the failure modes
of existing drugs and designing new inhibitors. Designing inhibitors that
mimic the structural features of the substrate was one such strategy shown
to handle resistance mutations eﬃciently [48, 5].
Inverse drug design (IDD) methodology [5] was developed in the Tidor
laboratory to explore the substrate envelope hypothesis as an inhibitor design
principle. The IDD method considers the ligand flexibility by sampling
conformations of the functional groups, and worked on an assumption that
the bound and the unbound state of the ligand and receptor hold the same
shape (rigid binding). Considering change in conformation of the receptor
and ligand upon binding often proves challenging due to its eﬀect on the
accuracy of binding energy computation, and due to the computational
time required to search the molecular search space. The ligand flexibility is
often handled by sampling the conformational space of the ligand/functional
groups. The receptor flexibility on the other hand in handled mainly by
sampling the side chain rotamers or by generating the protein ensembles
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using molecular mechanics.
This study capitalizes on the inverse design methodology for drug design
that was developed and tested on HIV-1 protease, and challenges the rigid
binding assumption [5]. To move beyond the rigid binding assumption and
consider nonrigid binding, a thermodynamic-cycle framework was devel-
oped and implemented that considers the conformational change of ligand
and receptor after binding while still remaining computationally eﬃcient
(maintaining a significant advantage of IDD to explore the molecular search
space). This framework included a four-step process to account for the
conformational change in ligand and receptor.
Inhibitors for HIV-1 protease considered the scaﬀold taken from the then
existing inhibitors. In this work, the scaﬀold was redesigned completely
— a de novo approach that involved systematic logical steps. The design
involved considering a core that can induce significant diversity with a
functional group that has shown potential to bind tightly to the receptor
with established mechanism of action. All possible functional groups and the
mechanism of inhibition were reviewed. One other careful consideration that
we included in deciding the side group libraries and in the scaﬀold design was
the feasibility of synthesis. For HCV NS3/4A protease, the scaﬀold design
included a triazine core for diversity and a ketoamide for inhibitor function
(known to inhibit serine proteases — in particular proven useful for HCV
NS3/4A protease) [38]. The synthesis requirement for the triazine moiety
includes primary or secondary amines at all three positions, or hydroxyl,
thiol and primary /secondary amine combination with the priority order:
Thiol > Amines > Alcohol. Hence we had to devise the possible mechanism
for attaching the functional group to the triazine core. Because the side
groups, which should include the ketoamide and a primary/secondary amine,
thiol or hydroxyl ending, were very limited in the chemical database search
results, a strategy described in Chapter 2 (section 2.5) was adopted. A
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smallest hydroxyl group containing ketoacid that is available in chemical
catalogue was obtained, and the ketoamides with hydroxyl ending to enable
attachment to the triazine core, was planned to be synthesized as shown
in Figure 2.13. The remaining two positions of the triazine core could be
targeted with primary or secondary amines. Thus we ensured the feasibility
of synthesis of the designed molecules.
Furthermore, the scaﬀold selection in the HIV-1 design was reported to
be a possible reason for the inhibitor-protease structure producing better
designed inhibitors over the substrate-protease structure. As the scaﬀold
considered in this study was developed from scratch, we carefully analyzed
all the available protein structures (as described in chapter 2 (section 2.2))
to select a protein structure for initial study.
In the case of HIV-1 protease, the substrate envelope was created from
overlaying the diﬀerent crystal substrates, while in case of HCV NS3/4A
protease where there is no substrate bound crystal structure, a dynamic
envelope was created. Though the dynamic envelope does not represent the
exact substrate conformations, it helped us to explore a flexible shape space
that was occupied by the substrate. The scaﬀold was found to dock well
making favorable interactions with the receptor.
The inverse drug design with conformational change that included a
constraint on the shape of the inhibitor, was employed to design inhibitors
for HCV NS3/4A protease that are predicted to have favorable binding
energetics and stay within the envelope. The scaﬀold when attached with
the side groups combinatorially (tested to attach to the diversity inducing
triazine moiety), generated the candidate molecules. The designed molecules
were found to fit well within the envelope. After a series of refinement the top
4 kcal ·mol−1 structures had 2020 conformations with 269 unique-molecules.
Further, they were verified to make favorable interactions with the receptor.
To compare the performance of the designed inhibitors with the currently
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available inhibitors, the binding energies were computed for each inhibitor.
The analysis showed that the designed inhibitors behave like the substrate
in analysis of individual energy terms. The currently available inhibitors, by
contrast, varied widely from the substrate. The more frequently preferred
side groups revealed to capture substrate-like interactions, and in addition
showed a preference for other strong interactions like sulphur-π interactions
remaining well within the envelope (Figure 3.10).
To further verify the inhibitors’ capacities to bind resistance mutants,
the mutations were modeled and analysis were carried out. As expected
for a design considering the shape constraint, the analysis showed that the
designed inhibitors remain robust while the current inhibitors were found
to be aﬀected in terms of binding energy. This computationally validates
the substrate envelope hypothesis. Another observation made during the
analysis was that mutations at the active site could protrude the envelope
(as in the case of A156 mutations).
Though all the designed inhibitors had a flat binding profile compared
to the commercial and candidate inhibitors considered, it further provided
us with an option to filter out the best performing compounds from the 269
unique molecules that were least aﬀected due to the considered mutations.
This showed that selective functional groups were preferred (Figure: 3.13)
that included groups not included in the top preferred list of functional
groups (Figure: 3.7). The common groups are highlighted.
Although the prediction could not be tested experimentally to support
our claims, the computational anaysis made use of the available experimen-
tal data to obtain accurate results. For instance, the respective inhibitor
bound protein structures were considered to compute their respective bind-
ing energies, instead of assuming the considered structure for designing
inhibitors. The assumptions considered might play an obstacle in obtaining
exact correlation with the available experimental data but nevertheless
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reflects the established claims about the existing types of inhibitors and
the mutations, and stands to support our results. One limitation of the
method includes requirement of the same atom centers for both bound and
unbound states, except at the place where conformational change occurs to
avoid ”grid errors” in grid-based calculations.
If the designed compounds were synthesized and experimentally tested,
the findings could help to improve the design. As done for the HIV protease,
the experimental binding energies and the predicted binding energies can
be checked for correlation. Further crystal structures could be obtained and
checked for the interactions and binding mode.
In summary, we have applied the inverse method to design robust in-
hibitors for the shallow, solvent exposed, substrate-binding groove of HCV
NS3/4A protease, using a serine trap warhead to covalently anchor the
inhibitor scaﬀold to the protease. The designed inhibitors were computation-
ally analyzed and found to be highly eﬃcient against resistance mutations.
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